| Literature DB >> 26423926 |
Jiraphun Jittikoon1, Surakameth Mahasirimongkol2, Angkana Charoenyingwattana3, Usa Chaikledkaew4, Pramote Tragulpiankit4, Supachoke Mangmool5, Wimala Inunchot2, Chayapol Somboonyosdes2, Nuanjun Wichukchinda2, Pathom Sawanpanyalert2, Yijing He6, Howard L McLeod6, Wasun Chantratita7.
Abstract
The objectives of this study are to investigate allele frequencies of drug absorption, distribution, metabolism and elimination (ADME)-related genes in the Thai population and to compare these genes to HapMap populations including Caucasians (CEU), Africans (YRI) and Asians (CHB/JPT). Genetic variations of drug ADME-related genes in 190 Thais were investigated using drug metabolizing enzymes and transporters (DMET) plus genotyping system. We examined 1936 single nucleotide polymorphisms (SNPs) of 225 genes that have documented functional and clinical significances in phase I and phase II drug metabolism enzymes, drug transporters and other genes involved in ADME processes. Distributions of genotyping data from Thai were compared with other HapMap populations including Caucasian, African and Asian populations. The analysis demonstrated 43 SNPs with statistical significance comparing among five populations. However, only 26 SNPs showed statistical significance in pair-wise comparisons between Thai versus CEU and Thai versus CHB/JPT. These 26 SNPs belong to 13 groups of drug ADME-related genes which are CYP2A6, CYP3A5, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, VKORC1, COMT, NAT2, TPMT, UGT1A1 and SLCO1B1. These genes demonstrated clinical significances as previously observed in many studies. The results could explain clinical variability in pharmacokinetics and pharmacodynamics of drugs in Thais based on genetic variations in drug ADME-related gene emphasized in this article.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26423926 DOI： 10.1038/jhg.2015.115
Source DB: PubMed Journal: J Hum Genet ISSN： 1434-5161 Impact factor: 3.172